30 closest matches · ranked by relevance
Prevention
Primary: Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis. — 1; 16; 1; 4 Participants — p=<0.001
Peptic Ulcer
Primary: Number of Participants in Whom Peptic Ulcer Was Healed — 66; 66 participants
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy — 7; 22 participants — p=0.005
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg — 10; 23 participants — p=0.020
Gastric or Duodenal Ulcers
Primary: Frequency of Adverse Drug Reactions — 1; 1; 1; 1 participants
Gastric Ulcer · Duodenal Ulcer
Primary: Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s). — 1.35; 1; 6.58 percentage of participants
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Cumulative Recurrent Rates of Gastric or Duodenal Ulcers — 2.8; 1.4; 21.7 Events/100 participants/24 weeks — p=<0.001
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) — 77.1; 83.8 Percentage of participants
Stomach Ulcer · Duodenal Ulcer
Primary: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer — 15; 46 participants — p=<0.0001
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
Peptic Ulcer
Primary: Recurrent Peptic Ulcer — 1; 9 participants
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants
Gastric or Duodenal Ulcers
Primary: Percentage of Participants Who Had One or More Adverse Drug Reactions — 1.79 Percentage of Participants
Venous Leg Ulcer
Primary: Time to Complete Healing of Reference Ulcer — 77; 69 days — p=0.246
Peptic Ulcer
Primary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants
Gastric Ulcer · Duodenal Ulcer · Rheumatoid Arthritis
Primary: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 167; 112 Participants
Aspirin Blood Level · Proton Pump Inhiditor Treatment
Primary: Aspirin Level in Blood (Area Under the Curve) — 49.4; 50.7; 8.7; 6.5 mg*hour/mL
Aspirin-Associated Gastric Ulcers
Primary: Number of Subjects Monitored for Long-term Safety of PA32540 — 379 participants
Gastric Ulcer
Primary: The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients…
Gastric or Duodenal Ulcers
Primary: Frequency of Adverse Drug Reactions — 1; 1; 1; 1 participants
Gastric Ulcer · Duodenal Ulcer · Rheumatoid Arthritis
Primary: Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 125 Participants
Peptic Ulcer
Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants
Marginal Ulcers
Primary: Number of Participants With Complaints, Specifically About Pain, Vomiting, Dyspepsia, and/or Dysphagia. — 17; 13 participants
Healthy
Primary: Change in Exhaled Inflammatory Mediator Levels — 1.42 pg/mL
Barrett Esophagus · Esophageal Cancer
Primary: Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples — -67.6; -123.9; -174.9 pg/mL — p=0.0955
Peptic Ulcer
Primary: Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy. — 40; 38 participants — p=0.0018
Type 2 Diabetes Mellitus · Coronary Artery Disease
Primary: Collagen Induced Aggregation — 32 percentage of platelet aggregation
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
Gastrointestinal Lesions
Primary: Endoscopic Score - Cryer Score — 4; 4 Cryer score
Hematology
Primary: Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration — 93.09; 87.71; 92.87; 98.72 percentage